• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by iBio Inc.

    1/31/25 5:13:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    S-8 1 tm254943d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on January 31, 2025

    Commission File No. 333-          

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    iBio, Inc.
    (Exact name of registrant as specified in its charter)
       
    Delaware 26-279813
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
       
    11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121
    (Address of Principal Executive Offices) (Zip Code)
     

    iBio, Inc.

    2023 Omnibus Incentive Plan

    (Full title of the plan)
     

    Martin Brenner, Ph.D. 

    Chief Executive Officer and 

    Chief Scientific Officer 

    11750 Sorrento Valley Road, Suite 200

    San Diego, CA 92121

    (858) 925-8215

    (Name and address of agent for service)

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Leslie Marlow, Esq.

    Melissa Palat Murawsky, Esq.

    Blank Rome LLP

    1271 Avenue of the Americas

    New York, New York 10020

    (212) 885-5000

    (Name, address and telephone number)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨  Accelerated filer ¨ 
    Non-accelerated filer x  Smaller reporting company x 
        Emerging growth company ¨ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

      

    INTRODUCTION

     

    iBio, Inc. (the “Registrant” or the “Company”) filed with the Securities and Exchange Commission (the “Commission”) its Registration Statement on Form S-8 (Registration No. 333-276452) on January 10, 2024 (the “2024 Registration Statement”), pursuant to and in accordance with the requirements of Form S-8 for the purpose of registering under the Securities Act of 1933, as amended (the “Securities Act”), 1,200,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issuable to employees, officers, directors, consultants and advisors of the Company under the Registrant’s 2023 Omnibus Incentive Plan (the “Plan”). Pursuant to General Instruction E to Form S-8, the 2024 Registration Statement is incorporated into this Registration Statement by reference. 

     

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering under the Securities Act an additional 458,383 shares of Common Stock, which is equal to 5% of 9,167,670, the number of shares of Common Stock outstanding on December 31, 2024, that may be issued pursuant to the Plan pursuant to an “evergreen” provision contained therein, resulting in a total of 1,658,383 shares of Common Stock available for issuance under the Plan.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information*

     

    Item 2. Registrant Information and Employee Plan Annual Information*

     

    *The information specified in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, as filed with the Commission, are incorporated by reference into this Registration Statement by the Registrant:

     

      · Our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on September 20, 2024, as amended September 24, 2024;  
         
      · Our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, filed with the SEC on November 12, 2024;
         
      · Our Current Reports on Form 8-K filed with the SEC on July 3, 2024, July 9, 2024, July 26, 2024, November 25, 2024 (other than information furnished under Item 2.02 and exhibits related thereto), January 2, 2025 (other than information furnished under Item 7.01 and exhibits related thereto), January 10, 2025 (other than information furnished under Item 7.01 and exhibits related thereto) and January 13, 2025; and  
         
      · The description of our Common Stock set forth in: (i) our registration statement on Form 8-A filed with the SEC on March 19, 2014, including any amendments thereto or reports filed for the purposes of updating this description, and (ii) Exhibit 4.2 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on September 20, 2024.

     

    All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part of this Registration Statement from the date of the filing of such documents.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, is or was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

     

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference.

     

    Exhibit   Description of Exhibit
         
    4.1   Certificate of Incorporation of iBio, Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on May 11, 2018 – Commission File No. 001-35023)
         
    4.2   Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 8, 2018 – Commission File No. 001-35023)
         
    4.3   Certificate of Designation, Preferences and Rights of the iBio CMO Preferred Tracking Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017 – Commission File No. 001-35023)
         
    4.4   Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 – Commission File No. 001-35023)
         
    4.5   Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 – Commission File No. 001-35023)
         
    4.6   Certificate of Designation, Preferences and Rights of the Series C Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2019 – Commission File No. 001-35023)
         
    4.7   Second Amended and Restated Bylaws of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2022 – Commission File No. 001-35023)
         
    4.8   Certificate of Designation of Preferences, Rights and Limitations of Series 2022 Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 – Commission File No. 001-35023)
         
    4.9   Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2022 – Commission File No. 001-35023)
         
    4.10   Certificate of Amendment to Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 28, 2023 – Commission File No. 001-35023)
         
    5.1*   Opinion of Blank Rome LLP.
         
    23.1*   Consent of Grassi & Co., CPAs, P.C., independent registered public accounting firm for the Registrant
         
    23.2*   Consent of Blank Rome LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on the signature page of this Registration Statement).

     

     

     

     

    99.1   iBio, Inc. 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on November 28, 2023– Commission File No. 001-35023).
         
    99.2   Form of Non-Qualified Stock Option Agreement for initial grants for non-employee directors under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.3   Form of Non- Qualified Stock Option Agreement for non-employee consultants under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.4   Form of Non-Qualified Stock Option Agreement for annual grants for non-employee directors under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.5   Form of Non-Qualified Stock Option Agreement for employees under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.6   Form of Restricted Stock Unit Award Agreement for employees under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.7   Form of Incentive Stock Option Agreement for employees under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    99.8   Form of Incentive Stock Option Agreement for officers under the iBio Omnibus Incentive Plan (incorporated by reference to Exhibit 10.7 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 9, 2024– Commission File No. 001-35023)
         
    107.1*   Filing Fee Table.

     

     

    *Filed herewith

     

     

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, California, on this 31st day of January, 2025.

     

        IBIO, INC.
         
      By: /s/ Martin Brenner
        Martin Brenner
        Chief Executive Officer and Chief Scientific Officer

     

    POWER OF ATTORNEY

     

    Each of the undersigned officers and directors of the Company hereby constitutes and appoints Martin Brenner and/or Marc Banjak as his or her true and lawful attorneys-in-fact and agents, severally, with full power of substitution and resubstitution, in his or her name and on his or her behalf, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power of authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

             
    Signature   Title   Date
         
    /s/ Martin Brenner     Chief Executive Officer and Chief Scientific Officer     January 31, 2025
    Martin Brenner   (Principal Executive Officer)    
         
    /s/ Felipe Duran      Chief Financial Officer   January 31, 2025
    Felipe Duran   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Alexandra Kropotova   Director   January 31, 2025
    Alexandra Kropotova        
         
    /s/ William Clark    Director   January 31, 2025
    William Clark    
             
    /s/ Gary Sender   Director   January 31, 2025
    Gary Sender    
             
    /s/ Evert Schimmelpennink    Director   January 31, 2025
    Evert Schimmelpennink         
             
     /s/ David Arkowitz   Director   January 31, 2025
     David Arkowitz        
             
    /s/ António Parada   Director   January 31, 2025
    António Parada        

     

     

    Get the next $IBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    10/21/2025$5.00Outperform
    Oppenheimer
    10/17/2025$2.00Outperform
    Leerink Partners
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on iBio with a new price target

    Oppenheimer initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00

    10/21/25 7:20:34 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on iBio with a new price target

    Leerink Partners initiated coverage of iBio with a rating of Outperform and set a new price target of $2.00

    10/17/25 8:34:58 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on iBio with a new price target

    Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

    5/28/24 7:42:07 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:02 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:33:31 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iBio Announces $26 Million Private Placement

    SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement ("PIPE") financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions. The financing was led by Frazier Life Sciences and included participation from other existing investors. iBio intends to use the net proc

    1/9/26 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio to Participate in the 8th Annual Evercore Healthcare Conference

    SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Thursday, December 4, 2025, at 8:45 a.m. ET. Dr. Brenner will outline iBio's ongoing efforts to move its next-generation obesity pipeline into clinical development, emphasizing the promising new non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, presented at ObesityWeek® 20

    11/24/25 4:15:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

    Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal quarter ended September 30, 2025, and provided a corporate update on its progress. "Unveiling our promising non-human primate data for IBIO-610, our lon

    11/12/25 4:01:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    1/30/26 6:16:28 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Duran Felipe

    4 - iBio, Inc. (0001420720) (Issuer)

    1/30/26 6:15:55 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Brenner Martin

    4 - iBio, Inc. (0001420720) (Issuer)

    1/30/26 6:15:07 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    SEC Filings

    View All

    SEC Form S-3 filed by iBio Inc.

    S-3 - iBio, Inc. (0001420720) (Filer)

    1/30/26 4:10:59 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by iBio Inc.

    SCHEDULE 13G - iBio, Inc. (0001420720) (Subject)

    1/22/26 5:02:57 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by iBio Inc.

    D - iBio, Inc. (0001420720) (Filer)

    1/22/26 4:01:42 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    View All

    iBio to Begin Trading on the Nasdaq Stock Exchange

    SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

    2/19/25 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Strengthens Board with Appointment of Two New Independent Directors

    SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

    11/25/24 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Reports Fiscal First Quarter 2025 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

    11/12/24 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by iBio Inc. (Amendment)

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    4/9/24 5:22:43 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Financials

    Live finance-specific insights

    View All

    iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

    6/24/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

    Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

    6/23/25 4:15:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

    – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

    3/27/24 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care